RHJA
GBT

Rice Hall James & Associates’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Rice Hall James & Associates’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-231,435
Closed -$7.39M – 279
2022
Q2 		$7.39M Sell
231,435
-152,317
-40% -$4.46M 0.36% 67
2022
Q1 		$13.3M Buy
383,752
+8,234
+2% +$246K 0.53% 55
2021
Q4 		$11M Sell
375,518
-34,263
-8% -$1.06M 0.39% 61
2021
Q3 		$10.4M Buy
409,781
+61,162
+18% +$1.8M 0.39% 67
2021
Q2 		$12.2M Sell
348,619
-50,686
-13% -$1.98M 0.43% 62
2021
Q1 		$16.3M Buy
399,305
+5,890
+1% +$271K 0.53% 54
2020
Q4 		$17M Buy
393,415
+72,488
+23% +$3.57M 0.6% 51
2020
Q3 		$17.7M Buy
320,927
+81,320
+34% +$5.17M 0.71% 43
2020
Q2 		$15.1M Buy
239,607
+17,352
+8% +$1.19M 0.65% 48
2020
Q1 		$11.4M Sell
222,255
-7,597
-3% -$509K 0.63% 48
2019
Q4 		$18.3M Sell
229,852
-5,910
-3% -$350K 0.62% 56
2019
Q3 		$11.4M Buy
235,762
+96,642
+69% +$5.04M 0.41% 94
2019
Q2 		$7.32M Buy
+139,120
New +$7.99M 0.24% 116

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Rice Hall James & Associates's GBT Position: Q3 2022 in Review

Rice Hall James & Associates sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 231,435 shares — an estimated $7.39M sold.

Rice Hall James & Associates first reported a position in GBT in Q2 2019 and held it in 13 quarters. The position peaked at $18.3M in Q4 2019. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Rice Hall James & Associates reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Rice Hall James & Associates sold 231,435 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $7.39M.
  • Rice Hall James & Associates first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 13 quarters.
  • Rice Hall James & Associates's Global Blood Therapeutics, Inc. position peaked at $18.3M in Q4 2019.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Rice Hall James & Associates's 13F filing for Q3 2022, filed 1 Nov 2022.